About This Event

Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Abraham N. Ceesay, CEO of Rapport Therapeutics, and David Bredt, M.D., Ph.D., Founder and Chief Scientific Officer of Rapport Therapeutics, ring the Closing Bell.